In vitro evaluation of the inhalable quercetin loaded nanoemulsion for pulmonary delivery
- 4 Downloads
Bioavailability of quercetin, a flavonoid potentially known to combat cancer, is challenging due to hydrophobic nature. Oil-in-water (O/W) nanoemulsion system could be used as nanocarrier for quercertin to be delivered to lung via pulmonary delivery. The novelty of this nanoformulation was introduced by using palm oil ester/ricinoleic acid as oil phase which formed spherical shape nanoemulsion as measured by transmission electron microscopy and Zetasizer analyses. High energy emulsification method and D-optimal mixture design were used to optimize the composition towards the volume median diameter. The droplet size, polydispersity index, and zeta potential of the optimized formulation were 131.4 nm, 0.257, and 51.1 mV, respectively. The formulation exhibited high drug entrapment efficiency and good stability against phase separation and storage at temperature 4 °C for 3 months. It was discovered that the system had an acceptable median mass aerodynamic diameter (3.09 ± 0.05 μm) and geometric standard deviation (1.77 ± 0.03) with high fine particle fraction (90.52 ± 0.10%), percent dispersed (83.12 ± 1.29%), and percent inhaled (81.26 ± 1.28%) for deposition in deep lung. The in vitro release study demonstrated that the sustained release pattern of quercetin from naneomulsion formulation up to 48 h of about 26.75% release and it was in adherence to Korsmeyer’s Peppas mechanism. The cytotoxicity study demonstrated that the optimized nanoemulsion can potentially induce cyctotoxicity towards A549 lung cancer cells without affecting the normal cells. These results of the study suggest that nanoemulsion is a potential carrier system for pulmonary delivery of molecules with low water solubility like quercetin.
KeywordsPalm oil ester Nanoemulsion Quercetin Pulmonary delivery D-optimal mixture design
The financial assistance provided from MyBRAIN 15 for Arbain N.H. by Ministry of Higher Education Malaysia (MOHE) and NanoMITe research grant (Vote. No. 5526306) were gratefully acknowledged.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl. Lung. Cancer Res. 2015;4:327–38.Google Scholar
- 3.Kumar A, Sahoo SK, Padhee K, Pal P, Kochar S, Satapathy A, et al. Reveiw on solubility enhancement techniques for hydrophobic drugs. Int J Compr Pharm. 2011;2:1–7.Google Scholar
- 18.Kelly GS, Gregory S, Kelly ND. Altern. Med Rev. 2011;16:172–94.Google Scholar
- 21.Solans C, Izquierdo P, Nolla J, Azemar N. Nano-emulsions. 2005;10:102–110.Google Scholar
- 38.Diab R, Brillault J, Bardy A, Gontijo AVL, Olivier JC. Formulation and in vitro characterization of inhalable polyvinyl alcohol-free rifampicin-loaded PLGA microspheres prepared with sucrose palmitate as stabilizer: efficiency for ex vivo alveolar macrophage targeting. Int J Pharm. 2012;436:833–9.CrossRefPubMedGoogle Scholar
- 40.Rahman M, Hasan S, Alam A, Roy S, Jha MK, Ahsan Q, et al. Formulation and evaluation of ranolazine sustained release matrix tablets using eudragit and HPMC. Int J PharmBiomed Res. 2011;2:7–12.Google Scholar